Stay updated on Sepofarsen Repeat-dose in LCA10 Clinical Trial
Sign up to get notified when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.

Latest updates to the Sepofarsen Repeat-dose in LCA10 Clinical Trial page
- Check6 days agoChange DetectedThe new screenshot appears to reflect minor formatting updates to the Study Details page without altering core trial information such as the NCT number, conditions, locations, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded a consolidated Locations section listing study sites in Iowa, Minas Gerais, São Paulo, Ontario, and Quebec. Removed the older individual location entries for those regions and the HHS Vulnerability Disclosure link.SummaryDifference0.6%

- Check20 days agoChange DetectedNo significant changes detected between the two screenshots. The page content and structure appear unchanged, including the study overview, eligibility criteria, and locations.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 on the page.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1. This indicates a minor page update without affecting study content.SummaryDifference0.0%

- Check49 days agoChange DetectedRemoved the banner about government funding and NIH operating status from the page. The study details and page structure remain unchanged.SummaryDifference0.4%

Stay in the know with updates to Sepofarsen Repeat-dose in LCA10 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.